Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Bibliographic Details
Main Authors:	Coates, LC, Rahman, P, Mease, PJ, Shawi, M, Rampakakis, E, Kollmeier, AP, Xu, XL, Chakravarty, SD, McInnes, IB, Tam, L-S
Format:	Journal article
Language:	English
Published:	BioMed Central 2024

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
by: Coates, LC, et al.
Published: (2024)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
by: Laura C. Coates, et al.
Published: (2024-02-01)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
by: Ritchlin, CT, et al.
Published: (2023)

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
by: Siebert, S, et al.
Published: (2024)

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis
by: Siebert, S, et al.
Published: (2024)

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
by: Rahman, P, et al.
Published: (2023)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
by: Laure Gossec, et al.
Published: (2024-02-01)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
by: Coates, L, et al.
Published: (2022)

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
by: Coates, LC, et al.
Published: (2021)

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study
by: Philip J. Mease, et al.
Published: (2024-12-01)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
by: Philip J. Mease, et al.
Published: (2023-10-01)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
by: Philip J Mease, et al.
Published: (2023-02-01)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
by: Christopher T. Ritchlin, et al.
Published: (2023-01-01)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
by: Joseph F Merola, et al.
Published: (2022-03-01)

Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
by: Jeffrey R. Curtis, et al.
Published: (2024-02-01)

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials
by: Jeffrey R. Curtis, et al.
Published: (2024-09-01)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
by: Dennis McGonagle, et al.
Published: (2023-04-01)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
by: Coates, L, et al.
Published: (2021)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
by: Dafna D. Gladman, et al.
Published: (2022-09-01)

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
by: Philip Mease, et al.
Published: (2024-09-01)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
by: Ritchlin, CT, et al.
Published: (2023)

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phase 3 study
by: Orbai, A-M, et al.
Published: (2022)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023-09-01)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
by: Georg Schett, et al.
Published: (2023-08-01)

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
by: Iain B McInnes, et al.
Published: (2024-12-01)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
by: Proton Rahman, et al.
Published: (2021-07-01)

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
by: Richard B. Warren, et al.
Published: (2024-03-01)

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
by: Georg Schett, et al.
Published: (2023-09-01)

Guselkumab: widened action in psoriatic disease
by: Marcelo Arnone, et al.
Published: (2021-05-01)

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
by: Christopher T. Ritchlin, et al.
Published: (2023-03-01)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
by: Yang Chen, et al.
Published: (2022-03-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
by: Orbai, A-M, et al.
Published: (2019)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
by: McInnes, IB, et al.
Published: (2023)

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial
by: Orbai, AM, et al.
Published: (2021)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
by: Merola, JF, et al.
Published: (2022)

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials
by: Stefan Siebert, et al.
Published: (2023-09-01)

Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2024-05-01)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
by: Mease, P, et al.
Published: (2017)

Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
by: Gossec, L, et al.
Published: (2024)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Similar Items

Similar Items